Amneal Lines Up Ready-To-Use Pemetrexed Hybrid

Q1 2024 Launch Planned After FDA Approval For Pemrydi 505(b)(2) Oncology Injectable

Amneal has set a launch date for its ready-to-use presentation of pemetrexed after the FDA approved the 505(b)(2) product under the name of Pemrydi.

Amneal
The FDA has approved Amneal’s Pemrydi RTU

Amneal says it is planning an early 2024 launch for its Pemrydi (pemetrexed) ready-to-use oncology injectable after the US Food and Drug Administration approved the product via the 505(b)(2) hybrid pathway.

Describing Pemrydi as “the first ready-to-use presentation of [this] key injectable,” Amneal said the product was indicated, in combination with...

Welcome to Generics Bulletin

Create an account to read this article

More from Products

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By 

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By 

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By 

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

More from Generics Bulletin

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By 

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By 

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By 

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.